Patient-centric initiatives are on the rise, including apps associated with the use of drugs and devices. Some of the most significant regulatory and legal questions around these initiatives relate to the necessity and feasibility of evaluating patient safety via such apps. The law has not quite caught up with our increasingly digitised world, and lapses in pharmacovigilance could occur in the resulting gap. Continue reading

See all Member News